CTLA4 and neoplasm: Although immune checkpoint inhibitors such as PD-1/CTLA-4 have made breakthroughs in multiple cancer types, PDAC has not been able to overcome treatment challenges due to its highly immunosuppressive tumor microenvironment and inherent chemotherapy resistance.